ProCE Banner Activity

Individualized Therapy and Molecular Targeting in AML

Slideset Download
In this downloadable slideset, Hagop M. Kantarjian, MD, discusses the use of biomarkers to guide treatment of patients with acute myeloid leukemia, including IDH, FLT3, and CD33/CD133.

Released: June 04, 2018

Expiration: June 03, 2019

No longer available for credit.

Share

Faculty

Hagop M. Kantarjian

Hagop M. Kantarjian, MD

Chairman, Department of Leukemia
Professor of Medicine
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Agios Pharmaceuticals

Bayer Healthcare Pharma

Celgene TEXT Only

Foundation Medicine

Loxo Oncology

Merck Oncology

Faculty Disclosure

Primary Author

Hagop M. Kantarjian, MD

Chairman, Department of Leukemia
Professor of Medicine
The University of Texas M.D. Anderson Cancer Center
Houston, Texas